FDA approves a new pain med that could eliminate addiction. When can GA patients get it?
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Daily16h
FDA Approves Suzetrigine, a First-in-Class Non-Opioid Painkiller
The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...
EURweb on MSN51m
FDA Approves New Non-Opioid Painkiller Journavx for Acute Pain | Watch
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Zacks.com on MSN5h
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
3 Magnificent Stocks to Buy and Hold Forever
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...
StudyFinds on MSN23h
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
Trump to Impose Tariffs on Canada, Mexico, and China
President Donald Trump on Saturday finalized tariffs, set to go into effect on Tuesday, at 10 percent on all Chinese goods, ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...
The Washington Post8h
FDA approves new, non-opioid painkiller Journavx
Wall Street analysts expect that Journavx, whose active ingredient is suzetrigine, could bring in about $100 million in sales this year. “We believe the opioid epidemic could be a priority for ...
Sierra Sun Times6h
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New Approaches for Pain Management
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...
Vertex stock price target raised to $550 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.